1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Plenty Of Potential For Roche's Entrectinib Despite Lack Of ESMO Enthusiasm

 
• By Kevin Grogan

Roche's up and down ESMO is best summed up by the response to data presented on its personalised cancer med entrectinib – good but perhaps not as good as others.

Star Trek
Set Phasers to Stun: Solid data from entrectinib's STARTRK trials • Source: Shutterstock

In the run-up to ESMO, much was made about how Roche's entrectinib and Bayer AG and Loxo Oncology Inc.'s larotrectinib would match up as treatments for patients with solid tumors who have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion and by the end of the Munich meeting, it looked like the Swiss giant has some catching-up to do.

An integrated analysis of 54 patients on the pivotal Phase II STARTRK-2, Phase I STARTRK-1 and Phase I ALKA-372-001 trials showed that entrectinib shrank tumors in 57.4% of people with NTRK fusion-positive solid tumors. A median duration of response of 10

More from Clinical Trials

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.